[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100579510":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":45,"collaborators":7,"id":47,"slug":7,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":7,"enrollmentInfo":55,"targetDuration":7,"studyType":58,"phases":7,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":67,"whyStopped":7,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de Besancon","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Charline Vauchy, PhD.","CONTACT","+33381218875","cvauchy@chu-besancon.fr",[15,33],{"facility":16,"status":7,"city":17,"state":7,"zip":18,"country":19,"countryCode":20,"cosmosGeoPoint":21,"geoPoint":26,"contacts":27},"Besançon University Hospital","Besançon","25000","France","FR",{"type":22,"coordinates":23},"Point",[24,25],6.01815,47.24878,{"lat":25,"lon":24},[28,30],{"name":29,"role":11,"phone":7,"phoneExt":7,"email":7},"Charline Vauchy, PhD",{"name":31,"role":32,"phone":7,"phoneExt":7,"email":7},"Melchior Chabannes, MD.","PRINCIPAL_INVESTIGATOR",{"facility":34,"status":7,"city":35,"state":7,"zip":36,"country":19,"countryCode":20,"cosmosGeoPoint":37,"geoPoint":41,"contacts":42},"Tours University Hospital","Tours","37044",{"type":22,"coordinates":38},[39,40],0.70398,47.39484,{"lat":40,"lon":39},[43],{"name":44,"role":32,"phone":7,"phoneExt":7,"email":7},"Bénédicte Sautenet, Prof.",{"type":46,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100579510",false,"NCT06825234","Prognostic Value of a Multidimensional Assessment for Survival in Elderly Patients With CKD 4B\u002F5","PROFILER","Inclusion Criteria:\n\n* Patients with CKD stage 4B or 5 (first consultation with GFR \\\u003C 20 mL\u002Fmin \u002F1.73 m2 in CKD-EPI 2009).\n* Fluency in French\n* Membership of a French social security scheme\n* Non-opposition from the subject to participate in the study\n\nExclusion Criteria:\n\n* Subjects with limited legal capacity.\n* Subjects still in the exclusion period of another study, or according to the national registry of clinical trial participants.\n* Subjects with no social security coverage.\n* Subjects judged by the investigator to be unlikely to comply with study procedures\n* Subjects unable to understand the reasons for the study; psychiatric disorders judged by the investigator to be incompatible with inclusion in the study.","ALL","75 Years",{"count":56,"type":57},390,"ESTIMATED","OBSERVATIONAL","The aim of this study is to determine a multidimensional signature (integrating frailty and patient-reported outcomes measures (PROMs) at entry into stage 4B\u002F5 CKD) to improve prediction of renal death (dialysis, transplantation, conservative management, death).",[61,62],"Chronic Kidney Disease Stage 5","Chronic Kidney Disease Stage 4B",[64,65,66],"Frailty","Patient-Related Outcomes","Personalised care","NOT_YET_RECRUITING","2025-04-30",{"date":70,"type":71},"2025-05-01","ACTUAL",{"date":73,"type":57},"2025-06",{"date":75,"type":57},"2028-12",{"name":5,"class":6},2]